The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus

Journal of Investigative Dermatology

Volumn 125, Issue 5, 2005, Pages 889-894

  Albrecht, Joerg ^a   Taylor, Lynne ^b   Berlin, Jesse A ^b   Dulay, Samuel ^a   Ang, Gina ^c   Fakharzadeh, Steven ^a,d   Kantor, Jonathan ^a   Kim, Ellen ^a   Militello, Giuseppe ^a   McGinnis, Karen ^a   Richardson, Stephen ^a   Treat, James ^a   Vittorio, Carmela ^a   Van Voorhees, Abby ^a   Werth, Victoria P ^a,d,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e Rhodes Pavillion ^*  (United States)

Author keywords

Clinical trial; Cutaneous lupus erythematosus; Discoid lupus erythematosus; Outcome instrument; Sub acute lupus erythematosus

Indexed keywords

ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; HUMAN; INTERRATER RELIABILITY; INTERVIEW; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDITY; CLINICAL TRIAL; HOSPITALIZATION; MULTICENTER STUDY; PROGNOSIS; SKIN LUPUS ERYTHEMATOSUS; VALIDATION STUDY;

HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 32844466113     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23889.x     Document Type: Article

References (25)

1. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE: Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol 141:185-191, 1999
2. Baughman RD, Sobel R: Psoriasis. A measure of severity. Arch Dermatol 101:390-395, 1970
3. Berth-Jones J, Thompson J, Graham-Brown RA: Evening primrose oil and atopic eczema. Lancet 345:520, 1995
4. Charman C, Williams H: Outcome measures of disease severity in atopic eczema. Arch Dermatol 136:763-769, 2000
5. Charman CR, Venn AJ, Williams HC: Measurement of body surface area involvement in atopic eczema: An impossible task? Br J Dermatol 140:109-111, 1999
6. Farrar JT, Berlin JA, Strom BL: Clinically important changes in acute pain outcome measures: A validation study. J Pain Symptom Manage 25:406-411, 2003
7. Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER: Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 133:1443-1448, 1997
8. Finlay AY: Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 135:509-515, 1996
9. Hanly JG: Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: Results of a cross-sectional study. Lupus 6:243-247, 1997
10. Hochbert MC, Engel EW, Pruitt A, et al: Correlations of disease activity with physical disability in SLE. Arthritis Rheum 222:333, 1990 abstract
11. Krueger G, Koo J, Menter A, Stern R, Rostad T: The impact of psoriasis on quality of life results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 137:280-284, 2001
12. Lahti A, Kopola H, Harila A, Myllyla R, Hannuksela M: Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter. Arch Dermatol Res 285:278-282, 1993
13. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 33:159-174, 1977
14. Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989
15. Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J: A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 35:559-565, 1996
16. Nichol MB, Margolies JE, Lippa E: The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 6:644-653, 1996
17. Parodi A, Massone C, Cacciapuoti M, Aragone MG, Bondavalli P, Cattarini G, Rebora A: Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br J Dermatol 142:457-460, 2000
18. Quinn AG, McLelland J, Essex T, Farr PM: Quantification of contact allergic inflammation: A comparison of existing methods with a scanning laser Doppler velocimeter. Acta Derm Venereol 73:21-25, 1993
19. Ramsay B, Lawrence CM: Measurement of involved surface area in patients with psoriasis. Br J Dermatol 124:565-570, 1991
20. Rider LG, Feldman BM, Perez MD, et al: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 40:1976-1983, 1997
21. SCORAD: Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 186:23-31, 1993
22. Streiner DL, Norman GR: Health Measurement Scales, A Practical Guide to their Development and Use, 2nd edn. Oxford: Oxford University Press, 1995
23. Tiling-Grosse S, Rees J: Assessment of area of involvement in skin disease: A study using schematic figure outlines. Br J Dermatol 128:69-74, 1993
24. Walter SD, Eliasziw M, Donner A: Sample size and optimal designs for reliability studies. Stat Med 17:101-110, 1998
25. Williams HC: Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol 133:1451-1452, 1997